Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SBRT Combined With PD-1/CTLA-4 Dual Antibody to Overcome Anti-PD-1 Resistant in Relapsed or Metastatic Esophageal Squamous Cell Carcinoma

NCT05732662 is registered in ClinicalTrials.gov with The First People's Hospital of Changzhou as lead sponsor.

NCT NCT05732662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05732662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SBRT Combined With PD-1/CTLA-4 Dual Antibody to Overcome Anti-PD-1 Resistant in Relapsed or Metastatic Esophageal Squamous Cell Carcinoma
Lead sponsor
The First People's Hospital of Changzhou
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2023
Completion date
December 31, 2026
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic esophageal squamous cell carcinoma